Abstract:OBJECTIVE:To evaluate the role of 2-deoxy-D-glucose (2-DG) modified supermagnetic iron oxide nanoparticles (SPIO) (γ-Fe2O3@DMSA-DG NPs) in tumor detection as a magnetic resonance imaging (MRI) contrast agent.METHODS:γ-Fe2O3@DMSA-DG NPs was prepared. The degree of A549 cells targeted absorption of γ-Fe2O3@DMSA-DG NPs was detected by Prussian blue staining, colorimetric assay, T2W and multi-echo sequence MRI. γ-Fe2O3@DMSA NPs was used as a control agent, and free D-glucose as a competitive inhibitor. Human lung adenocarcinoma A549 xenograft tumor was prepared in nude mice. Sterile aqueous suspension of γ-Fe2O3@DMSA NPs or γ-Fe2O3@DMSA-DG NPs was injected into the tail vein of nude mice. Before and 6, 12, 24, 48 h after injection, MRI imaging of the mice was performed. T2 signal intensity of the tumor, brain, liver and thigh skeletal muscles, and T2 values of the tumors were measured.RESULTS:The average diameter of the particles was about 10 nm, and there were no significant differences between the diameters of γ-Fe2O3@DMSA NPs and γ- Fe2O3@DMSA-DG NPs. The IR spectra showed the C-N retractable vibration peak at γ-Fe2O3@DMSA-DG NPs surface, indicating that 2-DG was conjugated to the γ-Fe2O3@DMSA NPs. The Prussian blue staining, colorimetric assay, MRI T2 signal intensity and T2 values revealed that γ-Fe2O3@DMSA-DG NPs were significantly more absorbed by A549 cells at growth peak than γ-Fe2O3@DMSA NPs, and the absorption of γ-Fe2O3@DMSA-DG NP was inhibited by free D-glucose. The results of in vivo examination showed that before and at 6, 12, 24, 48 h after injection of γ-Fe2O3@DMSA-DG NPs, the mean T2 signal intensities of the tumors were (326.00 ± 16.26)s, (276.40 ± 5.13)s, (268.40 ± 30.58)s, (240.40 ± 25.93)s, (262.20 ± 30.04)s, respectively, and the T2 values of the tumors were (735.80 ± 20.93) ms, (645.80 ± 69.58) ms, (615.00 ± 124.61) ms, (570.60 ± 67.78) ms, and (537.80 ± 105.29) ms, respectively. However, before and at 6, 12, 24, 48 h after injection of γ-Fe2O3@DMSA NPs, the mean T2 signal intensities of the tumors were (335.60 ± 4.93)s, (290.80 ± 5.93)s, (273.40 ± 15.08)s, (327.40 ± 16.65)s, and (313.20 ± 20.45)s, respectively, and T2 values were (686.00 ± 21.44)ms, (617.80 ± 69.93)ms, (645.20 ± 85.89)ms, (669.40 ± 13.72)ms, and (608.80 ± 61.90)ms, respectively. The T2 signal intensity and T2 value of the tumors were not declined generally after injection. The liver T2 signal intensity was decreased after injection of both γ-Fe2O3@DMSA-DG NPs and γ-Fe2O3@DMSA NPs, and T2 signal intensity of the brain and muscle did not show significant changes.CONCLUSIONS:γ-Fe2O3@DMSA-DG NPs has an ability to target glucose receptors overexpressed in tumors, and may serve as a MRI contrast agent for tumor detection.

Lactoferrin-conjugated Superparamagnetic Iron Oxide Nanoparticles As a Specific MRI Contrast Agent for Detection of Brain Glioma in Vivo.

Citric acid coated ultrasmall superparamagnetic iron oxide nanoparticles conjugated with lactoferrin for targeted negative MR imaging of glioma

Folic acid-conjugated superparamagnetic iron oxide nanoparticles for tumor-targeting MR imaging.

Pluronic F127-Folate Coated Super Paramagenic Iron Oxide Nanoparticles as Contrast Agent for Cancer Diagnosis in Magnetic Resonance Imaging

Dual-targeting and Excretable Ultrasmall SPIONs for T1-weighted Positive MR Imaging of Intracranial Glioblastoma Cells by Targeting the Lipoprotein Receptor-Related Protein

SPIO-Loaded Nanostructured Lipid Carriers for T2-weighted Magnetic Resonance Imaging of Hepatocarcinoma

2-Deoxy-d-glucose Modified Supermagnetic Iron Oxide Nanoparticles Enhance the Contrasting Effect on MRI of Human Lung Adenocarcinoma A549 Tumor in Nude Mice

Engineered Superparamagnetic Iron Oxide Nanoparticles (spions) for Dual-Modality Imaging of Intracranial Glioblastoma Via EGFRvIII Targeting

Iron oxide nanoclusters formed by acid-induced in situ calcium ion cross-linking for targeted magnetic resonance imaging of glioblastoma

Stem Cell Labeling With Superparamagnetic Iron Oxide Nanoparticles Using Focused Ultrasound And Magnetic Resonance Imaging Tracking

Magnetic Nanoparticles for MRI of Brain Tumors.

Doxorubicin and indocyanine green loaded superparamagnetic iron oxide nanoparticles with PEGylated phospholipid coating for magnetic resonance with fluorescence imaging and chemotherapy of glioma

Enhancing MRI imaging through high loading of superparamagnetic nanogels with high sensitivity to the tumor environment

Recent development in targeted MRI negative contrast based on ultra-small superparamagnetic iron oxide particles

Gadolinium-Loaded Solid Lipid Nanoparticles as a Tumor-Absorbable Contrast Agent for Early Diagnosis of Colorectal Tumors Using Magnetic Resonance Colonography.

In Vivo MR Imaging of Tumor by Using Fe3O4 Nanoparticles Bearing with Different Surface Ligand As Contrast Agent

A Functional Iron Oxide Nanoparticles Modified with PLA-PEG-DG As Tumor-Targeted MRI Contrast Agent

High MRI performance fluorescent mesoporous silica-coated magnetic nanoparticles for tracking neural progenitor cells in an ischemic mouse model.

Preparation and in Vitro Evaluation of a MRI Contrast Agent Based on Aptamer-Modified Gadolinium-Loaded Liposomes for Tumor Targeting

Targeting experimental orthotopic glioblastoma with chitosan-based superparamagnetic iron oxide nanoparticles (CS-DX-SPIONs)

Specific Targeting of Breast Tumor by Octreotide-Conjugated Ultrasmall Superparamagnetic Iron Oxide Particles Using a Clinical 3.0-Tesla Magnetic Resonance Scanner